6.78 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||6.77 x 800|
|Ask||6.80 x 1000|
|Day's Range||6.77 - 7.17|
|52 Week Range||4.07 - 12.95|
|Beta (3Y Monthly)||1.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]
Shares of thinly traded micro-cap biotech Minerva Neurosciences Inc (NASDAQ: NERV ) spiked higher on Monday. What Happened Minerva announced results of a Phase 2b study that evaluated its seltorexant, ...
Minerva Neurosciences Inc. shares soared 34% in premarket trade Monday, after the company said its trial of Seltorexant as a treatment for insomnia met its primary and key secondary goals. The company said the Phase 2b trial of the drug met its primary endpoint of latency to persistent sleep, or LPS, at Night 1 in 10 mg and 20 mg doses of Seltorexant. It also met its key secondary endpoint, defined as wake after sleep onset over first 6 hours at Night 1. The beneficial effects were maintained over time and were consistent in adults and elderly patients. "The findings from this study demonstrate that seltorexant significantly improves sleep induction and prolongs sleep duration," said Professor Thomas Roth, Director of the Sleep Disorders and Research Center at Henry Ford Hospital. "The results also demonstrate that seltorexant showed a significantly greater improvement in these sleep parameters compared to zolpidem." The study involved 365 patients with a mean age of 57.8, ranging from 22 to 84 years of age. Minerva shares have fallen 37.2% in 2019 through Friday, while the S&P 500 has gained 17.7%.
The drug was evaluated in adult patients with major depressive disorder who have responded inadequately to selective serotonin reuptake inhibitors and/or serotonin-norepinephrine reuptake inhibitors.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Does the May share price for Minerva Neurosciences, Inc. (NASDAQ:NERV) reflect what it's really worth...
The Waltham, Massachusetts-based company said it had a loss of 41 cents per share. Minerva Neurosciences shares have increased 12% since the beginning of the year. The stock has risen 22% in the last 12 ...
The Waltham, Massachusetts-based company said it had a loss of 34 cents per share. For the year, the company reported that its loss widened to $50.2 million, or $1.29 per share. Minerva Neurosciences shares ...
Every investor in Minerva Neurosciences, Inc. (NASDAQ:NERV) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see Read More...
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 31 cents. Minerva Neurosciences shares have risen 93 percent since the beginning of the year. The stock has increased ...
If you own shares in Minerva Neurosciences Inc (NASDAQ:NERV) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
Johnson & Johnson (JNJ) submits NDA to the FDA for esketamine nasal spray seeking approval for treatment-resistant depression in adults in the United States.